Out-licensing and Partnership Opportunities

The C3P3 expression system can be optimized for virtually any eukaryotic cell or organisms, offering a wide range of biotechnological opportunities.

Eukarÿs core business covers synthetic gene therapy and bioproduction tools. Eukarÿs can offer the opportunity for third-party companies to take a license on some of its technology components for the development of other applications, such as bioassays, vaccination, bioproduction and others.